Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Acetylation within the First 17 Residues of Huntingtin Exon 1 Alters Aggregation and Lipid Binding.

Chaibva M, Jawahery S, Pilkington AW 4th, Arndt JR, Sarver O, Valentine S, Matysiak S, Legleiter J.

Biophys J. 2016 Jul 26;111(2):349-62. doi: 10.1016/j.bpj.2016.06.018.

PMID:
27463137
2.

Cholesterol Modifies Huntingtin Binding to, Disruption of, and Aggregation on Lipid Membranes.

Gao X, Campbell WA 4th, Chaibva M, Jain P, Leslie AE, Frey SL, Legleiter J.

Biochemistry. 2016 Jan 12;55(1):92-102. doi: 10.1021/acs.biochem.5b00900. Epub 2015 Dec 22.

3.
4.

Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.

De Genst E, Chirgadze DY, Klein FA, Butler DC, Matak-Vinković D, Trottier Y, Huston JS, Messer A, Dobson CM.

J Mol Biol. 2015 Jun 19;427(12):2166-78. doi: 10.1016/j.jmb.2015.03.021. Epub 2015 Apr 8.

5.

Scalable production in human cells and biochemical characterization of full-length normal and mutant huntingtin.

Huang B, Lucas T, Kueppers C, Dong X, Krause M, Bepperling A, Buchner J, Voshol H, Weiss A, Gerrits B, Kochanek S.

PLoS One. 2015 Mar 23;10(3):e0121055. doi: 10.1371/journal.pone.0121055. eCollection 2015 Mar 23.

6.

Probing the Huntingtin 1-17 membrane anchor on a phospholipid bilayer by using all-atom simulations.

Côté S, Binette V, Salnikov ES, Bechinger B, Mousseau N.

Biophys J. 2015 Mar 10;108(5):1187-98. doi: 10.1016/j.bpj.2015.02.001.

7.

The emerging role of the first 17 amino acids of huntingtin in Huntington's disease.

Arndt JR, Chaibva M, Legleiter J.

Biomol Concepts. 2015 Mar;6(1):33-46. doi: 10.1515/bmc-2015-0001. Review.

8.

A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.

Yao Y, Cui X, Al-Ramahi I, Sun X, Li B, Hou J, Difiglia M, Palacino J, Wu ZY, Ma L, Botas J, Lu B.

Elife. 2015 Mar 4;4. doi: 10.7554/eLife.05449.

9.

Rescue of homeostatic regulation of striatal excitability and locomotor activity in a mouse model of Huntington's disease.

Cao Y, Bartolomé-Martín D, Rotem N, Rozas C, Dellal SS, Chacon MA, Kadriu B, Gulinello M, Khodakhah K, Faber DS.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2239-44. doi: 10.1073/pnas.1405748112. Epub 2015 Feb 2.

10.

Resolving the paradox for protein aggregation diseases: NMR structure and dynamics of the membrane-embedded P56S-MSP causing ALS imply a common mechanism for aggregation-prone proteins to attack membranes.

Qin H, Lim L, Wei Y, Gupta G, Song J.

Version 2. F1000Res. 2013 Oct 21 [revised 2014 Jul 22];2:221. doi: 10.12688/f1000research.2-221.v2. eCollection 2013 Oct 21.

11.

Conformational behavior and aggregation of ataxin-3 in SDS.

Saunders HM, Hughes VA, Cappai R, Bottomley SP.

PLoS One. 2013 Jul 22;8(7):e69416. doi: 10.1371/journal.pone.0069416. Print 2013.

12.

The interaction of polyglutamine peptides with lipid membranes is regulated by flanking sequences associated with huntingtin.

Burke KA, Kauffman KJ, Umbaugh CS, Frey SL, Legleiter J.

J Biol Chem. 2013 May 24;288(21):14993-5005. doi: 10.1074/jbc.M112.446237. Epub 2013 Apr 9.

13.

Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration.

Burke KA, Yates EA, Legleiter J.

Front Neurol. 2013 Mar 1;4:17. doi: 10.3389/fneur.2013.00017. eCollection 2013 Mar 1.

14.

The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling.

Moreira Sousa C, McGuire JR, Thion MS, Gentien D, de la Grange P, Tezenas du Montcel S, Vincent-Salomon A, Durr A, Humbert S.

EMBO Mol Med. 2013 Feb;5(2):309-25. doi: 10.1002/emmm.201201546. Epub 2013 Jan 9.

15.

Multifaceted roles of tunneling nanotubes in intercellular communication.

Marzo L, Gousset K, Zurzolo C.

Front Physiol. 2012 Apr 10;3:72. doi: 10.3389/fphys.2012.00072. eCollection 2012 Apr 10.

16.

Native mutant huntingtin in human brain: evidence for prevalence of full-length monomer.

Sapp E, Valencia A, Li X, Aronin N, Kegel KB, Vonsattel JP, Young AB, Wexler N, DiFiglia M.

J Biol Chem. 2012 Apr 13;287(16):13487-99. doi: 10.1074/jbc.M111.286609. Epub 2012 Feb 27.

17.

Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.

Reddy PH, Shirendeb UP.

Biochim Biophys Acta. 2012 Feb;1822(2):101-10. doi: 10.1016/j.bbadis.2011.10.016. Epub 2011 Nov 4. Review.

18.

Huntington's Disease and Striatal Signaling.

Roze E, Cahill E, Martin E, Bonnet C, Vanhoutte P, Betuing S, Caboche J.

Front Neuroanat. 2011 Aug 23;5:55. doi: 10.3389/fnana.2011.00055. eCollection 2011 Aug 23.

19.

Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.

Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH.

Hum Mol Genet. 2012 Jan 15;21(2):406-20. doi: 10.1093/hmg/ddr475. Epub 2011 Oct 13.

20.

Mass spectrometric identification of novel lysine acetylation sites in huntingtin.

Cong X, Held JM, DeGiacomo F, Bonner A, Chen JM, Schilling B, Czerwieniec GA, Gibson BW, Ellerby LM.

Mol Cell Proteomics. 2011 Oct;10(10):M111.009829. doi: 10.1074/mcp.M111.009829. Epub 2011 Jun 18.

Supplemental Content

Support Center